Evaluation of Urinary infections in Diabetic patients
Phase 2
Not yet recruiting
- Conditions
- Urinary tract infection, site notspecified,
- Registration Number
- CTRI/2019/12/022426
- Lead Sponsor
- The Himalaya Drug Company
- Brief Summary
This is an open label single arm clinicalstudy. Initially, subjects will be initiated for the informed consent processand then screening will be carried out for eligibility check.Subjects will bescreened to have 42 eligible subjects who will receive Cystone-SF liquid at adose of 10 ml twice daily for a period of 14 days. The whole study treatment isfor 14 days with follow up visit at day 1, 7 and 14. This study is divided intoScreening period, Active Treatment period and End of Study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Adult male and female subjects aged more than or equal too 18 years presenting atleast two of the following UTI symptoms like urgency, dysuria, frequency of micturition (nos), suprapubic pain, haematuria, burning micturition, fever, flank pain, chills, nausea and emesis.
- Known diabetic subjects with RBS less than or equal to 160 mg/dL.
- UTI as diagnosed by urine culture more than 105 CFU/mL Urine routine microscopy suggestive of increase or normal number of pus cells (white blood cells) per cubic millimetre Subjects willing to sign informed consent and follow the study procedure.
- Subjects who has not participated in any similar kind of clinical study in the last one month.
Exclusion Criteria
- History of neurogenic bladder, pelvic irradiation or chemical cystitis, Presence of urethral, pelvic, or rectal carcinoma, Benign or malignant bladder tumors, Tuberculous cystitis, urinary schistosomiasis.
- Subjects with cardiac, neurological, renal or hepatic dysfunction.
- Pregnant &breast-feeding women.
- Significant medical problems such as uncontrolled hypertension / congestive heart failure or any other medication condition History of ongoing, chronic or recurrent infectious disease / lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
- History of Alcohol or smoking abuse.
- Patients unwilling to provide informed consent or abide by the requirements of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subjects demonstrating percentage improvement in the terms of efficacy parameters such as laboratory and clinical parameters. The subject will be assessed clinically at day 7±3 days and at day 14±3 days (End of Study).
- Secondary Outcome Measures
Name Time Method Percentage of individuals symptoms free by day 7 (Table 1) Percentage of individuals symptoms free by day 14 (Table 1)
Trial Locations
- Locations (1)
ReSCUE The Urology Centre
🇮🇳Bangalore, KARNATAKA, India
ReSCUE The Urology Centre🇮🇳Bangalore, KARNATAKA, IndiaDr Chandrashekar S RatkalPrincipal investigator9845255378dr.csratkal@gmail.com